Skip to content

Incorrect allowed dosage on acetaminophen label could lead to overdose or death

Health Canada: 500 mg tablets sold in packages containing 1,000 and 100 caplets
A sign is displayed in front of Health Canada headquarters in Ottawa. (Sean Kilpatrick/The Canadian Press)

Health Canada has issued a recall for two lots of Novo-Gesic Forte Acetaminophen tablets distributed by Teva Canada because of a labelling error that could result in a person exceeding the maximum daily dosage for acetaminophen.

The 500 mg tablets were sold in packages containing 1,000 and 100 caplets, and were distributed in Canada starting Aug. 3, 2021. The affected bottles have an expiration date of June 2023, with the lot numbers 35364729A and 35217483A.

The label on the bottle of affected products incorrectly states “do not take more than 4,000 mg (12 tablets) in 24 hours.” However, the correct number of tablets should be eight.

Health Canada says consumers who follow the incorrect directions could ingest doses of acetaminophen ranging from 4,500 to 6,000 mg in 24 hours and experience symptoms of acetaminophen overdose.

Signs of acetaminophen overdose include nausea, vomiting, lethargy, sweating, loss of appetite and pain in the upper part of the abdomen or stomach. Abdominal pain may be the first sign of liver damage, which can result in liver failure or death.

To date, Teva Canada Limited has not received any reports of adverse events related to the lots being recalled.

Customers are being told to stop using the products, and to contact their local poison control centre or emergency health care services immediately if they think they have taken too much acetaminophen.

— The Canadian Press

Be Among The First To Know

Sign up for a free account today, and receive top headlines in your inbox Monday to Saturday.

Sign Up with google Sign Up with facebook

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Reset your password

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

A link has been emailed to you - check your inbox.

Don't have an account? Click here to sign up